CS
ARQT icon

Candriam SCA’s Arcutis Biotherapeutics ARQT Stock Holding History

Candriam SCA’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.9M Sell
949,839
-136,812
-13% -$3.19M 0.11% 172
2026
Q1 		$25.6M Buy
1,086,651
+283,513
+35% +$7.24M 0.13% 164
2025
Q4 		$23.3M Buy
803,138
+25,094
+3% +$642K 0.12% 175
2025
Q3 		$14.7M Sell
778,044
-12,391
-2% -$195K 0.08% 217
2025
Q2 		$11.1M Sell
790,435
-245,141
-24% -$3.44M 0.06% 236
2025
Q1 		$16.2M Sell
1,035,576
-6,568
-0.6% -$92.5K 0.1% 182
2024
Q4 		$14.5M Sell
1,042,144
-384,352
-27% -$4.21M 0.08% 212
2024
Q3 		$13.3M Buy
1,426,496
+119,015
+9% +$1.17M 0.08% 233
2024
Q2 		$12.2M Buy
+1,307,481
New +$11.8M 0.07% 232

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Candriam SCA's ARQT Position: Q2 2026 in Review

Candriam SCA reduced its Arcutis Biotherapeutics (ARQT) stake by 13% in Q2 2026, selling an estimated $3.19M and leaving 949,839 shares worth $24.9M. The position accounts for 0.11% of the portfolio, ranked #172.

Candriam SCA first reported a position in ARQT in Q2 2024 and has held it in 9 quarters since. The position peaked at $25.6M in Q1 2026. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Candriam SCA held 949,839 shares of Arcutis Biotherapeutics worth $24.9M as of Q2 2026.
  • Candriam SCA sold 136,812 Arcutis Biotherapeutics shares in Q2 2026, an estimated $3.19M.
  • Arcutis Biotherapeutics made up 0.11% of Candriam SCA's portfolio in Q2 2026, its #172 holding.
  • Candriam SCA first reported a position in Arcutis Biotherapeutics in Q2 2024 and has held it in 9 quarters since.
  • Candriam SCA's Arcutis Biotherapeutics position peaked at $25.6M in Q1 2026.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.